Register Login

All Posts

July 2025 CAP Today: A Deep Dive Into Key Hemostasis Testing Variables

Click A Deep Dive Into Key Hemostasis Testing Variables for an in-depth review of preanalytical hemostasis specimen concerns. The CAP article features Andrew Goodwin MD, professor, Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, and medical director of the thrombosis and hemostasis section, University of Vermont Medical Center; and Dr. […]
read more

July 2025 QQ: Hemophilia Rebalancing Therapy

Our July 2025 Quick Question asked, “Which is a hemophilia ‘rebalancing’ therapeutic?” The question attracted a modest 22 participants, perhaps an indication that rebalancing therapy was only FDA-approved in 2025 and awaits approval in Canada and Europe. Here are your responses… Valoctocogene roxaparvovec-rvox (ROCTAVIAN) 3 (14%) Efanesoctocog alfa (ALTUVIIIO) 1 (4%) Emicizumab (HemLibra) 7 (32%) […]
read more

Anti-Xa DOAC Assay Variability

Click here to read an open-access article describing the variability in assay methodology when monitoring apixaban and rivaroxaban: Baker RM, Selby R, Moffat KA, et al. Investigating interassay variability between direct oral anticoagulant calibrated anti-factor Xa assays: a substudy of the perioperative anticoagulation use for surgery evaluation (PAUSE) trial. Res Pract Thromb Haemost. 2025;9:102899. doi: 10.1016/j.rpth.2025.102899. […]
read more